A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

NCT05834348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5279

Last updated 2025-03-30

Study results available
· View outcomes & findings →

Summary

The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body.

This study includes patient's data from the database who:

* Are 18 years of age or older.
* Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022.

The study is based on data collection from 3 national health registries:

* The Cancer Registry of Norway (CRN),
* The Norwegian Patient Registry (NPR),
* The Norwegian Drug Registry (NDR).

Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes:

Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.

Conditions

Interventions

DRUG

lorlatinib

As provided in real world practice

DRUG

crizotinib

As provided in real world practice

DRUG

brigatinib

As provided in real world practice

DRUG

ceritinib

As provided in real world practice

DRUG

alectinib

As provided in real world practice

DRUG

atezolizumab

As provided in real world practice

DRUG

bevacizumab

As provided in real world practice

DRUG

paclitaxel

As provided in real world practice

DRUG

carboplatin

As provided in real world practice

DRUG

docetaxel

As provided in real world practice

DRUG

erlotinib

As provided in real world practice

DRUG

gefitinib

As provided in real world practice

DRUG

afatinib

As provided in real world practice

DRUG

dacomitinib

As provided in real world practice

DRUG

osimertinib

As provided in real world practice

DRUG

pembrolizumab

As provided in real world practice

DRUG

nivolumab

As provided in real world practice

DRUG

entrectinib

As provided in real world practice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2024-01-23
Completion
2024-01-23

Countries

  • Norway

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05834348 on ClinicalTrials.gov